Literature DB >> 16319720

Grey matter pathology in multiple sclerosis.

Marco Vercellino1, Federica Plano, Barbara Votta, Roberto Mutani, Maria Teresa Giordana, Paola Cavalla.   

Abstract

The aim of our study is to evaluate the extent and distribution of grey matter demyelinating lesions in multiple sclerosis (MS), addressing also neuronal loss and synaptic loss. Whole coronal sections of 6 MS brains and 6 control brains were selected. Immunohistochemistry was performed for myelin basic protein, neurofilaments, synaptophysin, ubiquitin, and activated caspase-3. Neuronal density and optical density of synaptophysin staining were estimated in cortical lesions and compared with those observed in corresponding areas of normal (i.e. nondemyelinated) cortex in the same section. Demyelinating lesions were observed in the cerebral cortex, in the thalamus, basal ganglia, and in the hippocampus. The percentage of demyelinated cortex was remarkable in 2 cases of secondary progressive MS (48% and 25.5%, respectively). Neuronal density was significantly reduced in cortical lesions (18-23% reduction), if compared with adjacent normal cortex, in the 2 cases showing the higher extent of cortical demyelination; in the same cases, very rare apoptotic neurons expressing caspase-3 were observed in cortical lesions and not in adjacent normal cortex. No significant decrease in optical density of synaptophysin staining was observed in cortical lesions. Grey matter demyelination and neuronal loss could contribute to disability and cognitive dysfunctions in MS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16319720     DOI: 10.1097/01.jnen.0000190067.20935.42

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  73 in total

Review 1.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

Review 2.  Pathogenic implications of iron accumulation in multiple sclerosis.

Authors:  Rachel Williams; Cassandra L Buchheit; Nancy E J Berman; Steven M LeVine
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

3.  In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI.

Authors:  Caterina Mainero; T Benner; A Radding; A van der Kouwe; R Jensen; B R Rosen; R P Kinkel
Journal:  Neurology       Date:  2009-07-29       Impact factor: 9.910

4.  Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis.

Authors:  Kedar R Mahajan; Kunio Nakamura; Jeffrey A Cohen; Bruce D Trapp; Daniel Ontaneda
Journal:  Ann Neurol       Date:  2020-05-01       Impact factor: 10.422

Review 5.  Grey matter damage in multiple sclerosis: a pathology perspective.

Authors:  Roel Klaver; Helga E De Vries; Geert J Schenk; Jeroen J G Geurts
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

Review 6.  Grey matter lesions in MS: from histology to clinical implications.

Authors:  Massimiliano Calabrese; Alice Favaretto; Valeria Martini; Paolo Gallo
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

Review 7.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

8.  Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice.

Authors:  Seema Tiwari-Woodruff; Rhonda R Voskuhl
Journal:  J Neurol Sci       Date:  2009-05-13       Impact factor: 3.181

9.  Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model.

Authors:  Priya Chaudhary; Gail Marracci; Danielle Galipeau; Edvinas Pocius; Brooke Morris; Dennis Bourdette
Journal:  J Neuroimmunol       Date:  2015-11-11       Impact factor: 3.478

10.  Cortical remyelination: a new target for repair therapies in multiple sclerosis.

Authors:  Ansi Chang; Susan M Staugaitis; Ranjan Dutta; Courtney E Batt; Kathryn E Easley; Anthony M Chomyk; V Wee Yong; Robert J Fox; Grahame J Kidd; Bruce D Trapp
Journal:  Ann Neurol       Date:  2012-10-17       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.